Abstract 1299P
Background
The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy after first-line durvalumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC).
Methods
A total of 122 patients with ES-SCLC from three hospitals during July 2019 to December 2021 were retrospectively analyzed. Inverse probability of treatment weighting (IPTW) analysis was performed to address potential confounding factors. We primarily evaluated the progression-free survival (PFS) and overall survival (OS) in association with radiotherapy.
Results
After IPTW analysis, 49 patients received durvalumab plus chemotherapy with subsequent radiotherapy (Durva+EP+RT) and 72 patients received immunochemotherapy (Durva+EP). The median OS was 17.2 vs 12.3 months (hazard ratio (HR): 0.38; P=0.020), respectively, and the median PFS was 8.9 vs 5.9 months (HR: 0.56; P=0.030), respectively. Thoracic radiation therapy (TRT) resulted in longer OS (17.2 vs 14.7 months) and PFS (9.1 vs 7.2 months) compared to radiotherapy directed to other metastatic sites. Among patients with oligo-metastasis, radiotherapy also showed significant benefits, with a median OS of 17.4 vs 13.7 months and median PFS of 9.8 vs 5.9 months compared to no radiotherapy. Continuous durvalumab treatment beyond progression (TBP) prolonged OS compared to patients without TBP, in both the Durva+EP+RT (NA vs 15.8 months, HR: 0.48) and Durva+EP groups (12.3 vs 4.3 months, HR: 0.29). Grade 3 or 4 adverse events occurred in 13 (26.5%) and 13 (18.1%) patients, respectively, in the two groups; pneumonitis was mostly low-grade.
Conclusions
Addition of radiotherapy after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bethune-Cancer Radiotherapy Translational Medicine Research Fund of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
466P - Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
Presenter: Lei Tang
Session: Poster session 04
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04